NOW THAT HENRY’S HEARTBURN WAS SOLVED, THAT JUST LEFT THE CASE TO CRACK.
With up to 12 hours fast-acting relief from indigestion and heartburn1
• Effectively helps to inhibit gastric acid secretion2,3 • Longer duration of action than antacids3 • Begins to work in as little as 30 minutes2 • All day or all night relief from one tablet1
® Ranitidine 75mg
Order now: Pack Size
Ranicalm® 12s
RRP* (£) £3.00
PIP Code 388-4384
EAN Code 506001394 3027
PRESCRIBING INFORMATION Product Name: Ranicalm® 75mg Film–coated tablets. Composition: Ranitidine 75mg. See SmPC for full list of excipients. Indication: Symptomatic relief of heartburn, indigestion, acid indigestion and hyperacidity. Posology and method of administration: Oral, to be swallowed whole with water. One tablet as soon as symptoms occur. If symptoms persist for more than one hour or return, take a second tablet. Do not take more than two tablets in 24 hours. Do not take for more than six days without the advice of a pharmacist or doctor. For prevention of acid indigestion, hyperacidity and heartburn, swallow one tablet with water half to one hour beforehand. Do not take tablets for more than two weeks continuously and seek medical advice if symptoms get worse or persist after two weeks. Children: (under 16 years of age): - Not recommended. Contraindications: Those with a known hypersensitivity to ranitidine or any of the tablet ingredients. Patients with severe renal impairment. Special warnings and precautions for use: Possibility of malignancy should be excluded before commencing therapy in patients with gastric ulcer, as ranitidine may mask symptoms of gastric carcinoma. Patients should seek medical advice from their doctor prior to taking the product if:- they are taking a non-steroidal anti-inflammatory drug (NSAID), have severe renal and / or hepatic impairment, are under regular medical supervision for other reasons, take either physician or self-prescribed medicines, have difficulty swallowing, persistent stomach pain or unintended weight loss associated with symptoms of indigestion, or are middle-aged or elderly patients with new or recently changed indigestion symptoms. Elderly patients and those with chronic lung disease, diabetes or who are immuno-compromised, are at an increased risk of developing community acquired pneumonia. Ranicalm® should be avoided in patients with porphyria. Interactions with other medicinal products: Potential inhibition with cytochromeP450 linked mixed function oxygenase system. Potential alteration of prothrombin time with coumarin anticoagulants (eg warfarin). High doses may reduce excretion of procainamide and N-acetylprocainamide leading to plasma increases. Potential increase in absorption of: triazolam, midazolam, glipizide. Potential decrease in absorption of ketoconazale, atazanavir, delaviridine, gefitinib. Please see SmPC for details. Pregnancy and lactation: Should not be taken in pregnancy or during breast feeding prior to consulting a doctor. Driving ability/use of machines: No known effect. Undesirable effects: The following are reported as rare (>1/10,000,<1/1000): Hypersensitivity reactions (reported after a single dose), transient and reversible changes in liver function tests, skin rashes, elevations of plasma creatinine. Reported as uncommon (>1/1000,<1/100): abdominal pain, constipation, nausea. Overdose: No particular problems are expected. Product Licence Holder: Bristol Laboratories Limited, Unit 3, Canalside Northbridge Road, Berkhamsted, Hertfordshire, HP4 1EG (PL 17907/0028 ) Date of Authorisation: 01/06/93 Recommended Price: £3.00 Date of Prescribing Information: 13.09.14 GSL
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bristol Laboratories Medical Information Department on Telephone: 0044 (0) 1442 200 922
References:
1. Ranicalm® SmPC. 2. Pappa. KA et al., Low-dose ranitidine for the relief of heartburn, Aliment Pharmacol Ther 1999;13:459-465. 3. Whitaker C, Gut Health Abdominal pain: indigestion, SAPA, 2012, 12 (4):22-23.
* Recommended Retail Price Date of preparation: February 2015 Job Code: UK/RAN/ADV40g/02/2015
Quality • Consistency • Excellence
www.bristol-labs.co.uk
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48